Stock Taper 
Haleon plc, headquartered in the UK, develops, manufactures, and sells consumer healthcare products worldwide, including brands like Panadol, Voltaren, and Sensodyne, across categories such as pain relief, oral health, respiratory, and supplements.
Haleon's innovative toothpaste, scientifically designed to protect against enamel erosion, is a flagship U.S. market product showcasing their commitment to science-backed oral care solutions.
Pfizer Inc. announced its plan to sell approximately 700 million ordinary shares in Haleon plc, representing about 7.7% of Haleon's issued share capital. This proposed secondary offering signaled a significant reduction in Pfizer's holding in the consumer health company, a move closely watched by investors for its potential impact on Haleon's stock and shareholder structure.
In 2025, Haleon announced a significant evolution of its operating model as part of its 'Win as One' strategy. This intentional shift includes the creation of new Chief Growth Officer and Chief Transformation Officer roles and a reorganization of its global business into six new Operating Units to enhance focus on key growth markets and simplify operations.
Investors interested in stocks from the Consumer Products - Discretionary sector have probably already heard of Lifetime Brands (LCUT) and Haleon PLC Sponsored ADR (HLN). But which of these two companies is the best option for those looking for undervalued stocks?
Overall rating: B+
| PEER | PRICE | |
|---|---|---|
 TAK | $17.86 | COMPARE |
 CAH | $228.30 | COMPARE |
 BDX | $176.80 | COMPARE |
 A | $167.77 | COMPARE |
 HUM | $388.36 | COMPARE |
 IQV | $258.21 | COMPARE |
 RMD | $218.89 | COMPARE |
 ALC | $63.76 | COMPARE |
